[go: up one dir, main page]

WO2018030838A1 - Composition comprenant des lactobacillus intestinalis pour la prévention ou le traitement de symptômes climatériques - Google Patents

Composition comprenant des lactobacillus intestinalis pour la prévention ou le traitement de symptômes climatériques Download PDF

Info

Publication number
WO2018030838A1
WO2018030838A1 PCT/KR2017/008738 KR2017008738W WO2018030838A1 WO 2018030838 A1 WO2018030838 A1 WO 2018030838A1 KR 2017008738 W KR2017008738 W KR 2017008738W WO 2018030838 A1 WO2018030838 A1 WO 2018030838A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lactobacillus intestinalis
lactobacillus
menopausal
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/008738
Other languages
English (en)
Korean (ko)
Inventor
남영도
김윤태
신희순
이소영
김재구
임은영
송은지
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Food Research Institute KFRI
Original Assignee
Korea Food Research Institute KFRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170101664A external-priority patent/KR101915904B1/ko
Application filed by Korea Food Research Institute KFRI filed Critical Korea Food Research Institute KFRI
Priority to US16/324,928 priority Critical patent/US11324785B2/en
Priority to JP2019507188A priority patent/JP6734471B2/ja
Publication of WO2018030838A1 publication Critical patent/WO2018030838A1/fr
Anticipated expiration legal-status Critical
Priority to US17/714,361 priority patent/US12016890B2/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus

Definitions

  • Figures 5a and 5b analyzed the cytokine concentration in the immune organs of the control group (Sham) and ovary extraction group (OVX) at 18 weeks after ovarian extraction surgery in female rats
  • Figure 5a is a variety of cytokines in the Peyers patch It is a result of measuring the concentration of the Cain (IL-1 ⁇ , 1 ⁇ , 2, 4, 6, 10, 12, 13, INF- ⁇ , TNF- ⁇ , GM, RANTES)
  • Figure 5b is the IL in the Peyers patch and spleen This is the result of measuring -10 concentration.
  • FIG. 6 shows PCA plotting total intestinal microbial changes in control (Sham) and ovary extraction groups (OVX) at 0, 1, 3, 6, 10, 14, and 18 weeks after ovarian extraction surgery in female rats. This is the result.
  • FIG. 9a and 9b is a food intake (Fig. 9a) and drinking water intake (Fig. 9a) of each experimental group from 1 to 16 weeks after ovarian extraction surgery to evaluate the effect of improving menopausal symptoms by Lactobacillus intestinalis administration This is the result shown by measuring.
  • the present inventors established a menopausal animal model through ovarian extraction, analyzed the intestinal microbial changes due to menopause, and studied the development of microbial material for improving menopausal symptoms. As a result, Lactobacillus intes significantly decreased in the menopausal animal model.
  • the present invention was completed by identifying and isolating Tinalis strains and confirming the effect of improving menopausal symptoms by Lactobacillus intestinalis comprising the strains.
  • the Lactobacillus intestinalis having a menopausal preventive or therapeutic effect is not only a novel strain (YT2) isolated and identified in feces of the menopausal rat model of the present invention, but also known in the prior art known Lactobacillus intestinalis By including all strains, the present invention is the first to identify the menopausal preventive or therapeutic effect of Lactobacillus intestinalis.
  • Lactobacillus intestinalis which showed the largest difference among the lactic acid bacteria whose distribution was significantly reduced in the ovarian extraction menopause model, was selected based on the result of Example 3, and the feces The strain was isolated from the sample (see Example 4).
  • the pharmaceutical composition according to the present invention contains Lactobacillus instinislis as an active ingredient, and may further include a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers are conventionally used in the preparation, and include, but are not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like. If necessary, other conventional additives such as antioxidants and buffers may be further included.
  • diluents, dispersants, surfactants, binders, lubricants and the like may be additionally added to formulate injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • Suitable pharmaceutically acceptable carriers and formulations can be preferably formulated according to the individual components using methods disclosed in Remington's literature.
  • the pharmaceutical composition of the present invention is not particularly limited in formulation, but may be formulated as an injection, inhalant, or external skin preparation.
  • the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, weight of the patient, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the type of disease, the drug used in general 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight may be administered daily or every other day, or divided into 1 to 3 times a day.
  • the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the present invention provides a food composition for menopausal improvement comprising Lactobacillus intestinalis ( Lactobacillus intestinalis ) including the novel strain as an active ingredient.
  • additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, One or more components selected from the group consisting of alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and pulp can be used.
  • compositions according to the invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and neutralizers, fact acids and their salts, alginic acids and their salts, organic acids, protective colloidal thickeners , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, etc.
  • other compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages.
  • fecal samples of Sham and OVX rats were recovered, and the metagenome was extracted. More specifically, 0.5g of the sample was homogenized using LN2, and after adding STES buffer, the cells were lysed at 60 ° C. overnight to lyse the cells. After cell lysis, metagenome was extracted using phenol extraction (PCI: phenol-chloroform-isoamylalcohol). Next, in order to remove RNA present on the crude metagenome, 10 ⁇ l (100 mg / ml) of RNase was incubated for 1 hour, and the purity available for sequencing using a DNA purification column was additionally determined. Eggplants obtained purified metagenome.
  • PCI phenol-chloroform-isoamylalcohol
  • Example 4 Intestinal microorganism discovery for relieving menopausal symptoms
  • the estradiol-treated group (OVX + Estradiol) and all the Lactobacillus intestinalis-treated group were found to have significantly increased bone density at 8, 12, and 16 weeks compared to the ovarian extraction group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une nouvelle souche YT2 de Lactobacillus intestinalis(numéro d'enregistrement : KCCM11812P) et une composition comprenant comme principe actif des Lactobacillus intestinalis, comprenant la nouvelle souche, pour la prévention, le soulagement ou le traitement de symptômes climatériques. Les présents inventeurs ont établi un modèle animal de la ménopause par ovariectomie, ont détecté un changement de composition du microbiote intestinal à l'aide de ce dernier, ont identifié et isolé une nouvelle souche de Lactobacillus intestinalis parmi les bactéries lactiques qui ont été significativement diminuées, en rapport, au sein de la composition du microbiote du modèle de la ménopause, et ont examiné les effets de soulagement apportés par la nouvelle souche et par les souches décrites classiquement de Lactobacillus intestinalis sur les symptômes climatériques, tels que la suppression de l'augmentation de la graisse corporelle, de la diminution de la densité osseuse, et de l'augmentation de la sensibilité à la douleur, et le soulagement de la dépression. Il est attendu que la composition comprenant Lactobacillus intestinalisde la présente invention soit utilisable pour la prévention, le soulagement ou le traitement des symptômes climatériques.
PCT/KR2017/008738 2016-08-12 2017-08-11 Composition comprenant des lactobacillus intestinalis pour la prévention ou le traitement de symptômes climatériques Ceased WO2018030838A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/324,928 US11324785B2 (en) 2016-08-12 2017-08-11 Composition for preventing or treating menopause, containing Lactobacillus intestinalis
JP2019507188A JP6734471B2 (ja) 2016-08-12 2017-08-11 ラクトバチルス・インテスティナーリスを含む更年期の予防または治療用組成物
US17/714,361 US12016890B2 (en) 2016-08-12 2022-04-06 Composition for preventing or treating menopause, containing Lactobacillus intestinalis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2016-0103281 2016-08-12
KR20160103281 2016-08-12
KR1020170101664A KR101915904B1 (ko) 2016-08-12 2017-08-10 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR10-2017-0101664 2017-08-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/324,928 A-371-Of-International US11324785B2 (en) 2016-08-12 2017-08-11 Composition for preventing or treating menopause, containing Lactobacillus intestinalis
US17/714,361 Division US12016890B2 (en) 2016-08-12 2022-04-06 Composition for preventing or treating menopause, containing Lactobacillus intestinalis

Publications (1)

Publication Number Publication Date
WO2018030838A1 true WO2018030838A1 (fr) 2018-02-15

Family

ID=61163065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008738 Ceased WO2018030838A1 (fr) 2016-08-12 2017-08-11 Composition comprenant des lactobacillus intestinalis pour la prévention ou le traitement de symptômes climatériques

Country Status (1)

Country Link
WO (1) WO2018030838A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111718873A (zh) * 2020-06-19 2020-09-29 江南大学 一株具有缓解骨质疏松功效的发酵乳杆菌及其应用
US20240376516A1 (en) * 2023-05-14 2024-11-14 TRAC Research, LLC Aseptic dissection and characterization of mixed microbial infections, display of microbe spatial relationships and lesion advancing fronts in human, veterinary, and botanical samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101279852B1 (ko) * 2011-06-29 2013-07-09 주식회사 쎌바이오텍 골다공증 예방 또는 치료용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101279852B1 (ko) * 2011-06-29 2013-07-09 주식회사 쎌바이오텍 골다공증 예방 또는 치료용 조성물

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
6 February 2017 (2017-02-06), pages 1 - 3, Retrieved from the Internet <URL:http://www.nspna.com/news/?mode=view&newsid=206436> *
BRITTON, ROBERT A. ET AL.: "Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 229, 27 March 2014 (2014-03-27), pages 1822 - 1830, XP055264927, DOI: doi:10.1002/jcp.24636 *
LECOMTE, VIRGINIE: "Changes in gut microbiota in rats fed a high fat diet correlate with obesity-associated metabolic parameters", PLOS ONE, vol. 10, no. 5, 18 May 2015 (2015-05-18), pages 1 - 22, XP055439774 *
LI, JAU-YI: "Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 6, 12 June 2016 (2016-06-12), pages 2049 - 2063, XP055603335, ISSN: 0021-9738, DOI: 10.1172/JCI86062 *
PARVANEH, KOLSOOM: "Effect of probiotics supplementation on bone mineral content and bone mass density", THE SCIENTIFIC WORLD JOURNAL, 22 January 2014 (2014-01-22), pages 1 - 6, XP055603326, ISSN: 2356-6140, DOI: 10.1155/2014/595962 *
THE EFFECTS OF PROBIOTICS ON MENOPAUSAL SYMPTOMS IN OVARIECTOMIZED RATS, February 2017 (2017-02-01), pages 1 - 67 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111718873A (zh) * 2020-06-19 2020-09-29 江南大学 一株具有缓解骨质疏松功效的发酵乳杆菌及其应用
US20240376516A1 (en) * 2023-05-14 2024-11-14 TRAC Research, LLC Aseptic dissection and characterization of mixed microbial infections, display of microbe spatial relationships and lesion advancing fronts in human, veterinary, and botanical samples
US12365931B2 (en) * 2023-05-14 2025-07-22 Trac Research, Inc. Aseptic dissection and characterization of mixed microbial infections, display of microbe spatial relationships and lesion advancing fronts in human, veterinary, and botanical samples

Similar Documents

Publication Publication Date Title
KR101867768B1 (ko) 락토바실러스 아시도필루스를 포함하는 갱년기 예방 또는 치료용 조성물
US12016890B2 (en) Composition for preventing or treating menopause, containing Lactobacillus intestinalis
WO2018012834A1 (fr) Souche d&#39;akkermansia muciniphila présentant un effet de prévention ou de traitement de maladies dégénératives du cerveau ou de maladies métaboliques et utilisation correspondante
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l&#39;obésité, et utilisation correspondante
WO2020091166A1 (fr) Nouvelles bactéries lactiques et leur utilisation
WO2015002393A1 (fr) Composition de traitement ou de prévention d&#39;une maladie cutanée inflammatoire comprenant, comme ingrédient actif, un extrait d&#39;agrumes immatures ou de la synéphrine, ou leur sel
WO2023038350A1 (fr) Composition pour soulager le syndrome prémenstruel, contenant des souches de lactobacillus mélangées en tant que principe actif
WO2018164325A1 (fr) Composition permettant de soigner les symptômes du syndrome climatère féminin
WO2021167350A1 (fr) Composition pour le traitement de trouble climatérique comprenant lactobacillus gasseri bnr17
WO2018030838A1 (fr) Composition comprenant des lactobacillus intestinalis pour la prévention ou le traitement de symptômes climatériques
WO2023038258A1 (fr) Nouvelle souche lactobacillus gasseri lm1065 issue du lait maternel, et composition pour soulager le syndrome prémenstruel comprenant ladite souche ou son produit de culture
WO2018030837A1 (fr) Composition pour la prévention ou le traitement de la ménopause, contenant lactobacillus acidophilus
WO2022045513A1 (fr) Composition pour la prévention ou le traitement de symptômes de la ménopause, comprenant du lactobacillus fermentum
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d&#39;une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l&#39;obésité comprenant un extrait embryonnaire de fève germée
US12324819B2 (en) Composition containing Enterococcus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
WO2019156465A1 (fr) Composition pour la prévention et le traitement de lésions de la moelle épinière
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
WO2019074235A1 (fr) Composition contenant alpha-asarone pour la prévention ou le traitement de lésion de la moelle épinière
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
Chello et al. Acne supplementation: probiotics, vitamins, and diet
WO2022158922A2 (fr) Composition comprenant une souche de propionibacterium freudenreichii mj2 utilisée en tant que principe actif pour la prévention, le traitement ou l&#39;atténuation de la polyarthrite rhumatoïde
WO2023140406A1 (fr) COMPOSITION PHARMACEUTIQUE COMPRENANT DU β-SITOSTÉROL POUR PRÉVENIR OU TRAITER LA SARCOPÉNIE
WO2023140407A1 (fr) Composition pharmaceutique comprenant du coumestrol pour la prévention ou le traitement de la sarcopénie
WO2023132738A1 (fr) Composition pour la prévention ou l&#39;atténuation de lésions cutanées, contenant un extrait végétal en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17839855

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019507188

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17839855

Country of ref document: EP

Kind code of ref document: A1